UroGen Pharma
UroGen Pharma is a United States-based pharmaceutical company running 3 late-stage cancer trials of UGN-103, UGN-102 and UGN-104 in bladder & urothelial cancer.
Overview
UroGen Pharma, based in Princeton, NJ, the United States, is a pharmaceutical company listed as NASDAQ: URGN. UroGen Pharma develops treatments for urothelial and specialty cancers, including its FDA-approved therapies Zusduri and Jelmyto, based on its proprietary RTGel reverse-thermal hydrogel technology. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing UGN-103, UGN-102 and UGN-104 in bladder & urothelial cancer. The largest, NCT05243550 (A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer), plans to enrol 240 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Scorecard
All companies- phase 3 +6
- modalities +2
UGN-103 is an experimental chemotherapy (mitomycin) delivered via hydrogel from UroGen Pharma in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.
UGN-104 is an experimental chemotherapy (mitomycin) delivered via hydrogel from UroGen Pharma in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.
Similar pages
not linked directly; found by shared links- CompanySuzhou Forlong Biotechnology
Shares Bladder & urothelial cancer and the tag ctgov-sponsor.
- CompanyMabwell (Shanghai) Bioscience
Shares Bladder & urothelial cancer and the tag ctgov-sponsor.
- CompanyMolecular Partners
Shares Bladder & urothelial cancer and the tag ctgov-sponsor.
- CompanyProtara Therapeutics
Shares Bladder & urothelial cancer and the tag ctgov-sponsor.
- CompanyLepu Biopharma
Shares Bladder & urothelial cancer and the tag ctgov-sponsor.